
피해자·유가족 358명, 청구액 13억7천400만원
건강보험심사평가원은 이태원 참사 피해자와 유가족 358명이 의료비 지원을 받았으며, 관련 건강보험 청구액은 13억7천400만원이라고 밝혔다. 신체·정신적 후유증 치료비 등을 지속 지원한다.
AI-generated summary
건강보험심사평가원은 '10·29 이태원 참사 피해자 권리보장과 진상규명 및 재발 방지를 위한 특별법' 등 관련법에 따라 피해자의 질병·부상과 후유증 치료에 들어가는 의료비를 지원하고 있다.
건강보험심사평가원(심평원)은 이달 현재 이태원 참사 피해자 의료비 지원과 관련한 건강보험 청구 기준 금액이 총 13억7천400만원이라고 12일 밝혔다.
이달까지 지원 대상자는 모두 358명이다.
심평원은 '10·29 이태원 참사 피해자 권리보장과 진상규명 및 재발 방지를 위한 특별법' 등 관련법에 따라 질병·부상과 후유증 치료에 들어가는 의료비를 지원하고 있다.
지원 항목은 급여 진료비, 의료비지원심의위원회를 거쳐 인정된 비급여 진료비, 원외처방 약제비, 보조장구 구입비 등이다.
피해자들이 신체적·정신적 회복에 필요한 치료를 받을 수 있도록 정신건강의학과 진료 등에 대한 의료비도 지원한다.
홍승권 심평원장은 "이태원 참사 피해자들이 치료와 회복에 필요한 지원을 받을 수 있도록 앞으로도 맡은 역할을 충실히 수행하겠다"고 말했다.

Jeju Island will expand childbirth medical support starting next year. Of the 23.3 billion won in the regional essential medical special account, 9.5 billion won will be invested in pediatric, childbirth, and maternal and child medical care to support securing medical personnel and expanding facilities and equipment. After 2023, there will be a total of 61 cases of transfer of Jeju mothers and newborns to other provinces.

The competition for GLP-1 type obesity drugs is expanding from injectable to oral. Eli Lilly has received approval for the oral obesity medicine 'Muyuda' in China, and Novo Nordisk is also seeking approval for 'Wegobi Pill' in China. In Korea, two companies have applied for product approval from the Ministry of Food and Drug Safety, and an edible obesity pill is expected to be released in Korea as early as next year.

About one in four deaths in South Korea last year was attributed to cancer, the country's leading cause of death, with 90,203 cancer deaths recorded—a 17.4 percent rise over the past decade. Lung and liver cancers remain the deadliest types, while pancreatic cancer mortality has surged and stomach cancer mortality has fallen. Regional disparities in mortality rates have widened, with Gwangju recording the highest rate and Seoul the lowest.

In Taiwan, the first application for relief from vision loss after using the GLP-1 obesity treatment drug Ozempic was filed. A man in his 50s was diagnosed with NAION after taking the drug for four months, and the Ministry of Food and Drug Safety announced that 12 of the 314 reports of suspected adverse reactions were eye-related.

The Seoul Metropolitan Government will invest 707.5 billion won by 2030 to promote a basic plan to support people with developmental disabilities. The key points include introducing a future life plan registration system, establishing autonomous district support centers, and strengthening support by life cycle.

In order to increase accessibility to over-the-counter medicines in areas where it is difficult to purchase medicines, such as military bases, local small and medium-sized airports, and drug-free villages, the government has legislated and administratively announced amendments to the Enforcement Decree of the Pharmaceutical Affairs Act and the Notice on Designation of Handling Medicines in Special Places. This includes allowing direct dispensing by military personnel, proxy handling of medicines for military units in remote areas, and expansion of handling of safety medicines at airport passenger terminals. The revised bill is scheduled to be finalized after collecting opinions.